Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, Cohort 3 Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

NCT03515044
View directory record Official record
Conditions
Overt Hepatic Encephalopathy
Interventions
40 mg Rifaximin SSD once daily, 40 mg Rifaximin SSD twice daily, 80 mg Rifaximin SSD once daily, 80 mg Rifaximin SSD twice daily, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
34
States / cities
Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

NCT05891236
View directory record Official record
Conditions
Malaria
Interventions
MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg
Biological · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

NCT01756404
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

NCT02780167
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-04965842, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Encinitas, California • Pasadena, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

NCT04044339
View directory record Official record
Conditions
Healthy
Interventions
TD-5202, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects

NCT03712163
View directory record Official record
Conditions
Healthy Subjects
Interventions
Norketotifen Oral Capsule (Cohort 1), Norketotifen Oral Capsule (Cohort 2), Norketotifen Oral Capsule (Cohort 3), Norketotifen Oral Capsule (Multiple Dose Cohort), Placebo Oral Capsule
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM

NCT03646721
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
DA-1241, Placebo, Sitagliptin
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 18, 2026, 6:15 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

NCT02967692
View directory record Official record
Conditions
Melanoma
Interventions
Spartalizumab, Placebo, Dabrafenib, Trametinib
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
12
States / cities
Encinitas, California • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

NCT05181709
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose, NDV-HXP-S IN high dose, NDV-HXP-S IM high dose
Drug · Biological
Lead sponsor
Sean Liu
Other
Eligibility
18 Years to 59 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants

NCT02153099
View directory record Official record
Conditions
Dose Finding Study
Interventions
TAK-058 (ENV8058), Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia

NCT03015532
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Saline Placebo, Bupivicaine HCl, Ropivacaine
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
24
States / cities
Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

NCT01105598
View directory record Official record
Conditions
Mild Dyslipidemia
Interventions
ETC-1002 or placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 18, 2026, 6:15 AM EDT
Withdrawn Not applicable Interventional

Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD

NCT03228121
View directory record Official record
Conditions
COPD, Emphysema or COPD, Chronic Bronchitis
Interventions
Treatment Then Placebo, Placebo Then Treatment
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 18, 2026, 6:15 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

NCT07575932
View directory record Official record
Conditions
Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity, Overnutrition, Nutrition Disorders, Nutritional and Metabolic Diseases, Body Weight
Interventions
PF-08653945, PF-08653944, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
53
States / cities
Sun City West, Arizona • Canoga Park, California • Fountain Valley, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults

NCT02674347
View directory record Official record
Conditions
Healthy Subjects
Interventions
3 g or 6 g Zidebactam, Placebo
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-951 in Healthy Adults

NCT05567393
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-951 Placebo, TAK-951
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 18, 2026, 6:15 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

NCT05387668
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-23339, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 18, 2026, 6:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774
View directory record Official record
Conditions
Spasticity
Interventions
Corabotase, Placebo, Dysport
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Safety and PK Study of IV TP-271

NCT03234738
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271, Placebo
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

NCT05647343
View directory record Official record
Conditions
Adverse Effect of Drugs and Medicaments in Therapeutic Use
Interventions
Ciclopirox Olamine Oral, Placebo
Drug · Other
Lead sponsor
Atlas Molecular Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

NCT00669942
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Anniston, Alabama • Tucson, Arizona • Largo, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole

NCT02234570
View directory record Official record
Conditions
Neurocysticercosis
Interventions
Oxfendazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 18, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants

NCT06316973
View directory record Official record
Conditions
Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
Interventions
CS-1103, Sterile Saline
Drug
Lead sponsor
Clear Scientific, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 18, 2026, 6:15 AM EDT